2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 26 March 2020Portfolio NewsSutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
25 March 2020Portfolio NewsBardy Diagnostics™ Announces Use of The Carnation Ambulatory Monitor Patch to Measure QT Segments in COVID-19 Patients Using Hydroxychloroquine
24 March 2020Portfolio NewsAlector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors
18 March 2020Portfolio NewsCOVID-19 Pulse from Evidation - to understand how Americans are coping with the spread of COVID-19
16 March 2020Portfolio NewsAVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update- 12 March 2020Portfolio NewsSutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck
10 March 2020Portfolio NewsBicycle Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates- 9 March 2020Portfolio NewsAVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis
- 9 March 2020Portfolio NewsDeciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results
4 March 2020Portfolio NewsSV Health Investors joins Xilio Therapeutics’ $100.5 million Series B financing - proceeds will advance XTX201 and XTX101 into the clinic while expanding Xilio’s cytokine pipeline
3 March 2020Portfolio NewsAmwell Launches National COVID-19 Telehealth Response Program- 2 March 2020Portfolio NewsEvelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases
